{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:42:11Z","timestamp":1792428131930,"version":"4.5.0"},"reference-count":120,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2502700"],"award-info":[{"award-number":["2022YFC2502700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.leukres.2026.108336","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:45:23Z","timestamp":1791441923000},"page":"108336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Beyond the binding site: PROTAC-mediated protein degradation assists the therapeutic paradigm of hematological malignancies"],"prefix":"10.1016","volume":"170","author":[{"given":"Mahsa","family":"Fatahichegeni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5511-4717","authenticated-orcid":false,"given":"Mohammad Amin","family":"Ansarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruimin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2026.108336_bib1","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1182\/blood-2023-187856","article-title":"Projected global trends in hematological malignancies: incidence, mortality, and disability-adjusted life years from 2020 to 2030","volume":"142","author":"An","year":"2023","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.leukres.2026.108336_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70224","article-title":"Trend analysis of hematological tumors in adolescents and young adults from 1990 to 2019 and predictive trends from 2020 to 2044: A Global Burden of Disease study","volume":"13","author":"Huang","year":"2024","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.leukres.2026.108336_bib3","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s11033-023-09096-8","article-title":"Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy","volume":"51","author":"Zafar","year":"2024","journal-title":"Mol. Biol. Rep."},{"issue":"12","key":"10.1016\/j.leukres.2026.108336_bib4","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/s41573-023-00807-1","article-title":"Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies","volume":"22","author":"Ruella","year":"2023","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"1","key":"10.1016\/j.leukres.2026.108336_bib5","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","article-title":"Targeted protein degradation: advances in drug discovery and clinical practice","volume":"9","author":"Zhong","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.leukres.2026.108336_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118201","article-title":"Construction of PROTAC molecules by the SuFEx reaction for inducing p300\/CBP protein degradation","volume":"125","author":"Guo","year":"2025","journal-title":"Bioorg. & Med. Chem."},{"issue":"4","key":"10.1016\/j.leukres.2026.108336_bib7","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1021\/acs.jmedchem.3c01468","article-title":"Discovery of novel PROTAC degraders of p300\/CBP as potential therapeutics for hepatocellular carcinoma","volume":"67","author":"Chang","year":"2024","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.leukres.2026.108336_bib8","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3390\/pharmaceutics17040501","article-title":"PROTAC Delivery Strategies for Overcoming Physicochemical Properties and Physiological Barriers in Targeted Protein Degradation","volume":"17","author":"Syahputra","year":"2025","journal-title":"Pharmaceutics"},{"issue":"D1","key":"10.1016\/j.leukres.2026.108336_bib9","doi-asserted-by":"crossref","first-page":"D1510","DOI":"10.1093\/nar\/gkae768","article-title":"PROTAC-DB 3.0: an updated database of PROTACs with extended pharmacokinetic parameters","volume":"53","author":"Ge","year":"2025","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"10.1016\/j.leukres.2026.108336_bib10","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1038\/d41591-024-00072-8","article-title":"PROTAC protein degraders to drug the undruggable enter phase 3 trials","volume":"30","author":"Arnold","year":"2024","journal-title":"Nat. Med."},{"issue":"26","key":"10.1016\/j.leukres.2026.108336_bib11","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1021\/acs.biochem.8b00391","article-title":"Targeting the C481S ibrutinib-resistance mutation in Bruton\u2019s tyrosine kinase using PROTAC-mediated degradation","volume":"57","author":"Buhimschi","year":"2018","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.leukres.2026.108336_bib12","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12943-024-02024-9","article-title":"New-generation advanced PROTACs as potential therapeutic agents in cancer therapy","volume":"23","author":"Wang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.leukres.2026.108336_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116154","article-title":"Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2","volume":"267","author":"Velez","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"6715","key":"10.1016\/j.leukres.2026.108336_bib14","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1126\/science.adm8684","article-title":"Targeting cancer with small-molecule pan-KRAS degraders","volume":"385","author":"Popow","year":"2024","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.leukres.2026.108336_bib15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41467-023-44237-4","article-title":"DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic-and acquired-degrader resistance","volume":"15","author":"Schr\u00f6der","year":"2024","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.leukres.2026.108336_bib16","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1535-7163.MCT-18-1129","article-title":"Acquired resistance to BET-PROTACs (proteolysis-targeting chimeras) caused by genomic alterations in core components of E3 ligase complexes","volume":"18","author":"Zhang","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.leukres.2026.108336_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2022.1610447","article-title":"A novel BRD family PROTAC inhibitor dBET1 exerts great anti-cancer effects by targeting c-MYC in acute myeloid leukemia cells","volume":"28","author":"Zhang","year":"2022","journal-title":"Pathol. Oncol. Res."},{"issue":"1","key":"10.1016\/j.leukres.2026.108336_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15384047.2022.2125748","article-title":"BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes","volume":"23","author":"Ma","year":"2022","journal-title":"Cancer Biol. & Ther."},{"issue":"16","key":"10.1016\/j.leukres.2026.108336_bib19","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1016\/j.molcel.2023.06.032","article-title":"Distinct layers of BRD4-PTEFb reveal bromodomain-independent function in transcriptional regulation","volume":"83","author":"Zheng","year":"2023","journal-title":"Mol. Cell."},{"issue":"5","key":"10.1016\/j.leukres.2026.108336_bib20","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1172\/JCI120654","article-title":"BETP degradation simultaneously targets acute myelogenous leukemic stem cells and the microenvironment","volume":"129","author":"Piya","year":"2019","journal-title":"J. Clin. Investig."},{"issue":"8","key":"10.1016\/j.leukres.2026.108336_bib21","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3390\/biomedicines8080245","article-title":"Mechanisms underlying resistance to FLT3 inhibitors in acute myeloid leukemia","volume":"8","author":"Eguchi","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.leukres.2026.108336_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107477","article-title":"Discovery of a potent Gilteritinib-based FLT3-PROTAC degrader for the treatment of Acute myeloid leukemia","volume":"149","author":"Ye","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"12","key":"10.1016\/j.leukres.2026.108336_bib23","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1038\/s41375-024-02405-5","article-title":"Selective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins","volume":"38","author":"Halilovic","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2026.108336_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216933","article-title":"FLT3-selective PROTAC: Enhanced safety and increased synergy with Venetoclax in FLT3-ITD mutated acute myeloid leukemia","volume":"592","author":"Tan","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.leukres.2026.108336_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116539","article-title":"Discovery of a potent CDKs\/FLT3 PROTAC with enhanced differentiation and proliferation inhibition for AML","volume":"275","author":"Wu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.leukres.2026.108336_bib26","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1021\/acs.jmedchem.2c01665","article-title":"Discovery of a potent and selective STAT5 PROTAC degrader with strong antitumor activity in vivo in acute myeloid leukemia","volume":"66","author":"Kaneshige","year":"2023","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.leukres.2026.108336_bib27","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/s41375-022-01735-6","article-title":"Z: An MDM2 degrader for treatment of acute leukemias","volume":"37","author":"Marcellino","year":"2023","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.leukres.2026.108336_bib28","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1021\/jacsau.4c00040","article-title":"Caflisch A: Proteolysis targeting chimera degraders of the METTL3\u201314 m6A-RNA methyltransferase","volume":"4","author":"Errani","year":"2024","journal-title":"JACS Au"},{"issue":"1","key":"10.1016\/j.leukres.2026.108336_bib29","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.chembiol.2023.12.009","article-title":"Discovery of a PROTAC degrader for METTL3-METTL14 complex","volume":"31","author":"Du","year":"2024","journal-title":"Cell. Chem. Biol."},{"key":"10.1016\/j.leukres.2026.108336_bib30","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood-2024-199212","article-title":"Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory Waldenstr\u00f6m Macroglobulinemia: results from the phase 1 CaDAnCe-101 study","volume":"144","author":"Seymour","year":"2024","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.leukres.2026.108336_bib31","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2425812122","article-title":"Discovery of an LSD1 PROTAC degrader","volume":"122","author":"Hosseini","year":"2025","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7","key":"10.1016\/j.leukres.2026.108336_bib32","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/s43018-024-00782-5","article-title":"Targeting a lineage-specific PI3K\u0263\u2013Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader molecule","volume":"5","author":"Kelly","year":"2024","journal-title":"Nat. Cancer"},{"issue":"12","key":"10.1016\/j.leukres.2026.108336_bib33","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1016\/j.apsb.2024.07.016","article-title":"Discovery of a potent PROTAC degrader for RNA demethylase FTO as antileukemic therapy","volume":"14","author":"Liu","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"13","key":"10.1016\/j.leukres.2026.108336_bib34","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1039\/D3SC06558H","article-title":"Discovery of potent PROTAC degraders of Pin1 for the treatment of acute myeloid leukemia","volume":"15","author":"Shi","year":"2024","journal-title":"Chem. Sci."},{"issue":"24","key":"10.1016\/j.leukres.2026.108336_bib35","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.leukres.2026.108336_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117420","article-title":"Design, synthesis, and biological evaluation of novel BTK-targeting proteolysis targeting chimeras (PROTACs) with enhanced pharmacokinetic properties","volume":"289","author":"Lin","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.leukres.2026.108336_bib37","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/bjh.17502","article-title":"Screening and monitoring of the BTK C481S mutation in a real-world cohort of patients with relapsed\/refractory chronic lymphocytic leukaemia during ibrutinib therapy","volume":"194","author":"B\u00f6d\u00f6r","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2026.108336_bib38","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2024-199116","article-title":"Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic Leukemia\/Small lymphocytic lymphoma: results from the phase 1 CaDAnCe-101 study","volume":"144","author":"Thompson","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108336_bib39","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2024-194839","article-title":"Efficacy and safety of the Bruton's tyrosine kinase (BTK) degrader NX-5948 in patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL): updated results from an ongoing phase 1a\/b study","volume":"144","author":"Shah","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108336_bib40","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-194009","article-title":"A phase 1 study of AC676, a novel BTK chimeric degrader, in patients with B-Cell malignancies","volume":"144","author":"Tees","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2026.108336_bib41","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3390\/cells13060528","article-title":"PROTAC-mediated dual degradation of BCL-xL and BCL-2 is a highly effective therapeutic strategy in small-cell lung cancer","volume":"13","author":"Khan","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.leukres.2026.108336_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1196005","article-title":"BCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival","volume":"13","author":"Champion","year":"2023","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2026.108336_bib43","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1038\/s41467-024-46922-4","article-title":"Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL","volume":"15","author":"Nayak","year":"2024","journal-title":"Nat. Commun."},{"issue":"14","key":"10.1016\/j.leukres.2026.108336_bib44","doi-asserted-by":"crossref","first-page":"11868","DOI":"10.1021\/acs.jmedchem.4c00481","article-title":"Development of an Orally Bioavailable LCK PROTAC Degrader as a Potential Therapeutic Approach to T-Cell Acute Lymphoblastic Leukemia","volume":"67","author":"Jarusiewicz","year":"2024","journal-title":"J. Med. Chem."},{"issue":"15","key":"10.1016\/j.leukres.2026.108336_bib45","doi-asserted-by":"crossref","first-page":"13197","DOI":"10.1021\/acs.jmedchem.4c01134","article-title":"Discovery of a Highly Potent, Selective and Efficacious USP7 Degrader for the Treatment of Acute Lymphoblastic Leukemia","volume":"67","author":"Xu","year":"2024","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.leukres.2026.108336_bib46","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/carcin\/bgae006","article-title":"The BET inhibitor GNE-987 effectively induces anti-cancer effects in T-cell acute lymphoblastic leukemia by targeting enhancer regulated genes","volume":"45","author":"Yu","year":"2024","journal-title":"Carcinogenesis"},{"issue":"6682","key":"10.1016\/j.leukres.2026.108336_bib47","doi-asserted-by":"crossref","DOI":"10.1126\/science.adi5798","article-title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127","volume":"383","author":"Montoya","year":"2024","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.leukres.2026.108336_bib48","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa2303194","article-title":"Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma","volume":"389","author":"Richardson","year":"2023","journal-title":"New. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.leukres.2026.108336_bib49","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.3390\/cancers14184492","article-title":"CRL4CRBN E3 ligase complex as a therapeutic target in multiple myeloma","volume":"14","author":"Barankiewicz","year":"2022","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.leukres.2026.108336_bib50","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.3324\/haematol.2024.285636","article-title":"Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond","volume":"110","author":"Teoh","year":"2024","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.leukres.2026.108336_bib51","article-title":"Pharmacodynamic changes in tumor and immune cells drive iberdomide\u2019s clinical mechanisms of activity in relapsed and refractory multiple myeloma","volume":"5","author":"Amatangelo","year":"2024","journal-title":"Cell. Rep. Med."},{"key":"10.1016\/j.leukres.2026.108336_bib52","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.5c01022","article-title":"Development of a Selective and Potent PRMT4 PROTAC Degrader with Efficacy against Multiple Myeloma in Vitro and in Vivo","author":"Ju","year":"2025","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.leukres.2026.108336_bib53","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/s41467-022-28515-1","article-title":"Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma","volume":"13","author":"Ng","year":"2022","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.leukres.2026.108336_bib54","first-page":"705","article-title":"Treatment of dexamethasone and lenalidomide-resistant multiple myeloma via RAD51 degradation using PROTAC and synergistic effects with chemotherapy","volume":"75","author":"Kim","year":"2024","journal-title":"J. Physiol. PHARMACOLOGY"},{"key":"10.1016\/j.leukres.2026.108336_bib55","article-title":"Novel PROTAC to target FKBP12: the potential to enhance bone morphogenetic protein activity and apoptosis in multiple myeloma","author":"Quist-Lokken","year":"2020","journal-title":"Haematologica"},{"issue":"22","key":"10.1016\/j.leukres.2026.108336_bib56","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1182\/blood.2024025861","article-title":"Evaluating the impact of CRBN mutations on response to immunomodulatory drugs and novel cereblon E3 ligase modulators in myeloma","volume":"145","author":"Chrisochoidou","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2026.108336_bib57","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1158\/2643-3230.BCD-23-0061","article-title":"ETV4-dependent transcriptional plasticity maintains MYC expression and results in IMiD resistance in multiple myeloma","volume":"5","author":"Neri","year":"2024","journal-title":"Blood Cancer Discov."},{"issue":"14","key":"10.1016\/j.leukres.2026.108336_bib58","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1158\/1078-0432.CCR-24-0256","article-title":"MYC inhibition potentiates CD8+ T cells against multiple myeloma and overcomes immunomodulatory drug resistance","volume":"30","author":"Davis","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"15","key":"10.1016\/j.leukres.2026.108336_bib59","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/blood.2023021105","article-title":"Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML","volume":"143","author":"Bourgeois","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108336_bib60","article-title":"Discovery of a Proteolysis-Targeting Chimera Degrader of JAK2 as a Potential Therapeutic Agent for JAK2-Mediated Myeloproliferative Neoplasms","author":"Wang","year":"2025","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.leukres.2026.108336_bib61","first-page":"2313","article-title":"Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia","volume":"138","author":"Chang","year":"2021","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"10.1016\/j.leukres.2026.108336_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1430833","article-title":"Type II mode of JAK2 inhibition and destabilization are potential therapeutic approaches against the ruxolitinib resistance driven myeloproliferative neoplasms","volume":"14","author":"Gorantla","year":"2024","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2026.108336_bib63","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00280-022-04490-8","article-title":"Resistance to the BCL-XL degrader DT2216 in T-cell acute lymphoblastic leukemia is rare and correlates with decreased BCL-XL proteolysis","volume":"91","author":"Jaiswal","year":"2023","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.leukres.2026.108336_bib64","first-page":"62","article-title":"Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor","volume":"142","author":"Gomez","year":"2023","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"7","key":"10.1016\/j.leukres.2026.108336_bib65","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it?","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"3","key":"10.1016\/j.leukres.2026.108336_bib66","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/17407745231207085","article-title":"Statistical and practical considerations in planning and conduct of dose-optimization trials","volume":"21","author":"Yuan","year":"2024","journal-title":"Clin. Trials"},{"key":"10.1016\/j.leukres.2026.108336_bib67","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.3722","article-title":"Dose Optimization in Oncology Drug Development: Risk Factors for Postmarketing Requirements and Commitments","author":"Kitagaki","year":"2025","journal-title":"Clin. Pharmacol. & Ther."},{"issue":"3","key":"10.1016\/j.leukres.2026.108336_bib68","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41589-022-01177-2","article-title":"Functional E3 ligase hotspots and resistance mechanisms to small-molecule degraders","volume":"19","author":"Hanzl","year":"2023","journal-title":"Nat. Chem. Biol."},{"issue":"12","key":"10.1016\/j.leukres.2026.108336_bib69","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity","volume":"25","author":"Khan","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.leukres.2026.108336_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1516419","article-title":"Antibody-drug conjugates in cancer therapy: applications and future advances","volume":"16","author":"Long","year":"2025","journal-title":"Front. Immunol."},{"issue":"18","key":"10.1016\/j.leukres.2026.108336_bib71","doi-asserted-by":"crossref","first-page":"15996","DOI":"10.1021\/acs.jmedchem.4c01289","article-title":"The new frontier: merging molecular glue degrader and antibody\u2013drug conjugate modalities to overcome strategic challenges","volume":"67","author":"Poudel","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.leukres.2026.108336_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116216","article-title":"What influences the activity of Degrader\u2212 Antibody conjugates (DACs)","volume":"268","author":"Guo","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.leukres.2026.108336_bib73","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13045-025-01674-6","article-title":"Breakthroughs in treatment for hematological malignancies: latest updates on molecular glue, PROTACs and RNA degraders from ASH 2024","volume":"18","author":"Li","year":"2025","journal-title":"J. Hematol. & Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2026.108336_bib74","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40580-024-00421-w","article-title":"Microneedle-mediated nanomedicine to enhance therapeutic and diagnostic efficacy","volume":"11","author":"Zuo","year":"2024","journal-title":"Nano Converg."},{"issue":"12","key":"10.1016\/j.leukres.2026.108336_bib75","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3390\/bioengineering10121368","article-title":"Recent Advances in Optically Controlled PROTAC","volume":"10","author":"Ouyang","year":"2023","journal-title":"Bioengineering"},{"issue":"7","key":"10.1016\/j.leukres.2026.108336_bib76","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.cell.2026.01.029","article-title":"The E3-ome gene-centric compendium reveals the human E3 ligase landscape","volume":"189","author":"Chua","year":"2026","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.leukres.2026.108336_bib77","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.1038\/s41467-023-42233-2","article-title":"Expanding PROTACtable genome universe of E3 ligases","volume":"14","author":"Liu","year":"2023","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.leukres.2026.108336_bib78","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202500102","article-title":"Ternary Complex Modeling, Induced Fit Docking and Molecular Dynamics Simulations as a Successful Approach for the Design of VHL-Mediated PROTACs Targeting the Kinase FLT3","volume":"358","author":"Nassar","year":"2025","journal-title":"Arch. der Pharm."},{"key":"10.1016\/j.leukres.2026.108336_bib79","doi-asserted-by":"crossref","DOI":"10.1039\/D4DD00177J","article-title":"A comprehensive review of emerging approaches in machine learning for de novo PROTAC design","author":"Gharbi","year":"2024","journal-title":"Digit. Discov."},{"issue":"7","key":"10.1016\/j.leukres.2026.108336_bib80","doi-asserted-by":"crossref","first-page":"6650","DOI":"10.1021\/acsomega.4c08049","article-title":"Molecular Glue-Design-Evaluator (MOLDE): An Advanced Method for In-Silico Molecular Glue Design","volume":"10","author":"Ben Geoffrey","year":"2025","journal-title":"ACS Omega"},{"issue":"1","key":"10.1016\/j.leukres.2026.108336_bib81","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2023-179872","article-title":"A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed\/Refractory B Cell Malignancies","volume":"142","author":"Danilov","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108336_bib82","article-title":"A first-in-human study of the potent and highly selective BTK degrader ABBV-101 in patients with relapsed\/refractory B-cell malignancies","author":"Chong","year":"2024","journal-title":"In. Am. Soc. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.leukres.2026.108336_bib83","first-page":"CT12","article-title":"Abstract CT128: Phase 1 study of HSK29116, a Bruton tyrosine kinase (BTK) proteolysis-targeting chimera (PROTAC) agent, in patients with relapsed or refractory B-cell malignancies","volume":"83","author":"Li","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2026.108336_bib84","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1182\/blood-2021-147473","article-title":"Nx-5948, a selective degrader of BTK with activity in preclinical models of hematologic and brain malignancies","volume":"138","author":"Robbins","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108336_bib85","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2019-125820","article-title":"DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), is a potent anti T-cell lymphoma agent that does not induce significant thrombocytopenia","volume":"134","author":"He","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2026.108336_bib86","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.3324\/haematol.2022.281915","article-title":"Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells","volume":"108","author":"Jia","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.leukres.2026.108336_bib87","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1182\/blood-2024-210301","article-title":"Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors","volume":"144","author":"Feldman","year":"2024","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2026.108336_bib88","doi-asserted-by":"crossref","first-page":"7197","DOI":"10.1021\/acs.jmedchem.4c00051","article-title":"Discovery of a novel orally bioavailable FLT3-PROTAC degrader for efficient treatment of acute myeloid leukemia and overcoming resistance of FLT3 inhibitors","volume":"67","author":"Wang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.leukres.2026.108336_bib89","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.5c00831","article-title":"Discovery of Potent Dual PROTAC Degraders Targeting BET-Kinase To Overcome FLT3 Inhibitor Resistance","author":"Xiang","year":"2025","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.leukres.2026.108336_bib90","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3324\/haematol.2018.201483","article-title":"Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations","volume":"104","author":"Lim","year":"2019","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.leukres.2026.108336_bib91","doi-asserted-by":"crossref","first-page":"19503","DOI":"10.1021\/acs.jmedchem.4c01818","article-title":"Discovery of MD-265: a potent MDM2 degrader that achieves complete tumor regression and improves long-term survival of mice with leukemia","volume":"67","author":"Aguilar","year":"2024","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.leukres.2026.108336_bib92","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41589-022-01248-4","article-title":"A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo","volume":"19","author":"Kaneshige","year":"2023","journal-title":"Nat. Chem. Biol."},{"issue":"11","key":"10.1016\/j.leukres.2026.108336_bib93","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1158\/1535-7163.MCT-24-1091","article-title":"PROTAC-mediated degradation of TAF1 induces apoptosis in AML cells and inhibits tumor growth in vivo","volume":"24","author":"Chen","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.leukres.2026.108336_bib94","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1182\/blood-2023-187496","article-title":"Targeted protein degradation for c-MYC overcomes therapy resistance in T-cell acute lymphoblastic leukemias","volume":"142","author":"Munir","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108336_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216128","article-title":"PROTACs: Novel tools for improving immunotherapy in cancer","volume":"560","author":"Li","year":"2023","journal-title":"Cancer Lett."},{"issue":"13","key":"10.1016\/j.leukres.2026.108336_bib96","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1182\/blood.2023022993","article-title":"Degraders upgraded: the rise of PROTACs in hematological malignancies","volume":"143","author":"Casan","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2026.108336_bib97","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.7150\/thno.92526","article-title":"Degraders in epigenetic therapy: PROTACs and beyond","volume":"14","author":"Dai","year":"2024","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.leukres.2026.108336_bib98","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12935-024-03271-y","article-title":"Super enhancer related gene ANP32B promotes the proliferation of acute myeloid leukemia by enhancing MYC through histone acetylation","volume":"24","author":"Wan","year":"2024","journal-title":"Cancer Cell. Int."},{"key":"10.1016\/j.leukres.2026.108336_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116717","article-title":"FLT3-PROTACs for combating AML resistance: Analytical overview on chimeric agents developed, challenges, and future perspectives","volume":"277","author":"Hesham","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"13","key":"10.1016\/j.leukres.2026.108336_bib100","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1200\/JCO.23.01911","article-title":"Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML","volume":"42","author":"Short","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2026.108336_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108532","article-title":"Functional genomics identify distinct and overlapping genes mediating resistance to different classes of heterobifunctional degraders of oncoproteins","volume":"34","author":"Shirasaki","year":"2021","journal-title":"Cell. Rep."},{"issue":"49","key":"10.1016\/j.leukres.2026.108336_bib102","doi-asserted-by":"crossref","first-page":"33675","DOI":"10.1021\/jacs.4c11556","article-title":"Leveraging Dual-Ligase Recruitment to Enhance Protein Degradation via a Heterotrivalent Proteolysis Targeting Chimera","volume":"146","author":"Bond","year":"2024","journal-title":"J. Am. Chem. Soc."},{"issue":"12","key":"10.1016\/j.leukres.2026.108336_bib103","doi-asserted-by":"crossref","first-page":"8281","DOI":"10.1021\/acs.jmedchem.3c00740","article-title":"Physicochemical property determinants of oral absorption for PROTAC protein degraders","volume":"66","author":"Hornberger","year":"2023","journal-title":"J. Med. Chem."},{"issue":"19","key":"10.1016\/j.leukres.2026.108336_bib104","doi-asserted-by":"crossref","first-page":"12639","DOI":"10.1021\/acs.jmedchem.2c00201","article-title":"Designing soluble PROTACs: strategies and preliminary guidelines","volume":"65","author":"Garc\u00eda Jim\u00e9nez","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.leukres.2026.108336_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115793","article-title":"Current advances and development strategies of orally bioavailable PROTACs","volume":"261","author":"Zeng","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.leukres.2026.108336_bib106","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s42003-025-08104-w","article-title":"Cellular parameters shaping pathways of targeted protein degradation","volume":"8","author":"Cardno","year":"2025","journal-title":"Commun. Biol."},{"issue":"3","key":"10.1016\/j.leukres.2026.108336_bib107","doi-asserted-by":"crossref","DOI":"10.1002\/mabi.202400427","article-title":"PROTAC and Molecular Glue Degraders of the Oncogenic RNA Binding Protein Lin28","volume":"25","author":"Kashkush","year":"2025","journal-title":"Macromol. Biosci."},{"issue":"12","key":"10.1016\/j.leukres.2026.108336_bib108","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1021\/acschembio.3c00598","article-title":"Discovery of molecular glue degraders via isogenic morphological profiling","volume":"18","author":"Ng","year":"2023","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.leukres.2026.108336_bib109","article-title":"Molecular Glues Recruiting RNF213 As an E3 Ligase for Targeted Protein Degradation: A Minimal Dibromoacetamide Warhead As a Recruitment Ligand","author":"Jiang","year":"2026","journal-title":"J. Am. Chem. Soc."},{"issue":"10","key":"10.1016\/j.leukres.2026.108336_bib110","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202500035","article-title":"Replacing a Cereblon Ligand by a DDB1 and CUL4 Associated Factor 11 (DCAF11) Recruiter Converts a Selective Histone Deacetylase 6 PROTAC Into a Pan-Degrader","volume":"20","author":"Feller","year":"2025","journal-title":"ChemMedChem"},{"issue":"20","key":"10.1016\/j.leukres.2026.108336_bib111","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202515159","article-title":"Discovery of SKP2-Recruiting PROTACs for Target Protein Degradation","volume":"13","author":"Dong","year":"2026","journal-title":"Adv. Sci."},{"key":"10.1016\/j.leukres.2026.108336_bib112","first-page":"1","article-title":"DCAF11-dependent molecular glue degrader activated by glutathionylation","author":"Yoon","year":"2026","journal-title":"Nature"},{"issue":"22","key":"10.1016\/j.leukres.2026.108336_bib113","article-title":"Conditional PROTAC: recent strategies for modulating targeted protein degradation","volume":"19","author":"Yim","year":"2024","journal-title":"ChemMedChem"},{"issue":"12","key":"10.1016\/j.leukres.2026.108336_bib114","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1016\/j.ymthe.2023.10.020","article-title":"A genetically encoded protein tag for control and quantitative imaging of CAR T cell therapy","volume":"31","author":"Lee","year":"2023","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.leukres.2026.108336_bib115","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202400682","article-title":"Precise Modulation of Protein Degradation by Smart PROTACs","volume":"26","author":"Cheng","year":"2025","journal-title":"ChemBioChem"},{"issue":"1","key":"10.1016\/j.leukres.2026.108336_bib116","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2023.2247253","article-title":"BRD4 PROTAC degrader MZ1 exhibits anti-B-cell acute lymphoblastic leukemia effects via targeting CCND3","volume":"28","author":"Ma","year":"2023","journal-title":"Hematology"},{"issue":"22","key":"10.1016\/j.leukres.2026.108336_bib117","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202104823","article-title":"A Temporal PROTAC Cocktail-Mediated Sequential Degradation of AURKA Abrogates Acute Myeloid Leukemia Stem Cells","volume":"9","author":"Liu","year":"2022","journal-title":"Adv. Sci."},{"issue":"4","key":"10.1016\/j.leukres.2026.108336_bib118","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1158\/1535-7163.MCT-23-0747","article-title":"PROTACs: current and future potential as a precision medicine strategy to combat cancer","volume":"23","author":"Rutherford","year":"2024","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.leukres.2026.108336_bib119","first-page":"42","article-title":"Computational strategies for PROTAC drug discovery","volume":"2","author":"Wu","year":"2023","journal-title":"Acta Mater. Med."},{"issue":"5","key":"10.1016\/j.leukres.2026.108336_bib120","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbae358","article-title":"DiffPROTACs is a deep learning-based generator for proteolysis targeting chimeras","volume":"25","author":"Li","year":"2024","journal-title":"Brief. Bioinforma."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626001803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626001803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:08:11Z","timestamp":1792426091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626001803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":120,"alternative-id":["S0145212626001803"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108336","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond the binding site: PROTAC-mediated protein degradation assists the therapeutic paradigm of hematological malignancies","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108336","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108336"}}